Muscle loss and GLP-1R agonists use

Area of Science:

• Endocrinology
• Metabolic Diseases
• Sarcopenia Research

Background:

• Skeletal muscle wasting (sarcopenia) is a critical complication in diabetes mellitus and obesity, worsening insulin resistance and mortality.
• Metabolic diseases increase sarcopenia risk due to inflammation, mitochondrial dysfunction, and altered protein metabolism.
• Glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively treat type 2 diabetes and obesity but can cause lean body mass loss.

Purpose of the Study:

• To review the epidemiology and mechanisms of muscle loss in diabetes and obesity.
• To analyze the impact of GLP-1RA therapy on lean body mass.
• To examine strategies for preserving muscle health during GLP-1RA treatment.

Main Methods:

• Comprehensive literature search of English-language studies on muscle mass loss during GLP-1RA therapy.
• Inclusion of data from major scientific databases and clinical trial registries.
• Narrative synthesis of current knowledge and examination of preventive/therapeutic strategies.

Main Results:

• GLP-1RA therapy is associated with a decrease in lean body mass in patients with type 2 diabetes and obesity.
• This finding raises concerns for individuals predisposed to sarcopenia.
• Integrated management strategies are needed to address muscle loss during weight reduction.

Conclusions:

• GLP-1RAs offer significant benefits but necessitate attention to muscle health.
• Preventive and therapeutic interventions are crucial to mitigate sarcopenia risk.
• Further research and practical insights are needed to maximize GLP-1RA benefits while preserving muscle mass.